Jason Rhodes Sells 147,760 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 147,760 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $21.13, for a total value of $3,122,168.80. Following the completion of the sale, the director directly owned 1,106,036 shares of the company’s stock, valued at $23,370,540.68. The trade was a 11.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $20.94 on Friday. The stock has a market cap of $3.46 billion, a P/E ratio of -6.50 and a beta of 1.09. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The stock has a 50 day moving average of $18.45 and a two-hundred day moving average of $18.11. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the previous year, the business earned ($1.05) EPS. On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on DYN. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. HC Wainwright dropped their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Finally, Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $34.17.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Creative Planning increased its position in Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after buying an additional 1,440 shares during the period. Hilton Head Capital Partners LLC purchased a new stake in shares of Dyne Therapeutics in the first quarter valued at approximately $26,000. Caxton Associates LLP boosted its stake in shares of Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.